参照文献

1. Robinson DG, et al. Psychopharmacological treatment in the RAISE-ETP study: outcomes of a manual and computer decision support system based intervention. Am J Psychiatry 2018; 175:169–179.
2. Zhu Y, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4:694–705.
3. Zhang JP, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013; 16:1205–1218.
4. Leucht S, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005; 57:1543–1549.
5. Agid O, et al. The ‘delayed onset’ of antipsychotic action–an idea whose time has come and gone. J Psychiatry Neurosci 2006; 31:93–100.
6. Kahn RS, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder （OPTiMiSE）: a three-phase switching study. Lancet Psychiatry 2018; 5:797–807.
7. Subotnik KL, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. a randomized clinical trial. JAMA Psychiatry 2015; 72:822–829.
8. Schreiner A, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015; 169:393–399.
9. Alphs L, et al. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Intervention in Psychiatry 2018; 12:55–65.
10. Kane JM, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication （Long-Acting Injectable Antipsychotics）: results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 2019; 80:18m12546.
11. Agid O, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72:1439–1444.
12. Drosos P, et al. One-year outcome and adherence to pharmacological guidelines in first-episode schizophrenia: results from a consecutive cohort study. J Clin Psychopharmacol 2020; 40:534–540.
13. Davis JM, et al. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553–564.
14. Leucht S, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31–41.
15. Schooler N, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:947–953.
16. Oosthuizen PP, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64:1075–1080.
17. Whiskey E, et al. Evaluation of an antipsychotic information sheet for patients. Int J Psychiatry Clin Pract 2005; 9:264–270.
18. Stroup TS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107:1–12.
19. Olofinjana B, et al. Antipsychotic drugs – information and choice: a patient survey. Psychiatric Bulletin 2005; 29:369–371.
20. Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611–622.
21. Haro JM, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26:571–578.
22. Novick D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes （SOHO） study. Schizophr Res 2009; 108:223–230.
23. Tiihonen J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333:224.
24. Leucht S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.
25. Remington G, et al. The use of electronic monitoring （MEMS） to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007; 90:229–237.
26. McCutcheon R, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018; 137:39–46.
27. Takeuchi H, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 2019; 44:1036–1042.
28. McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600–610.
29. Lewis SW, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32:715–723.
30. Mace S, et al. Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics. Ther Adv Psychopharmacol 2019; 9:2045125319860977.